HIV Risk and Prevalence among New York City Injection Drug Users

2015 National HIV Behavioral Surveillance Study



Background & Methods

Background

- NYC has a large population of IDUs
- In 2014, 2% of new HIV diagnoses in NYC were attributable to injection drug use (direct injection risk)
- The number of new HIV diagnoses among people with a history of injection drug use (IDU) in NYC has decreased over the course of the epidemic
 - Largely based on the success of sterile syringe access programs and increased safe injection practices by NYC IDUs
- Yet ongoing sexual and injection-related risk among IDU persist



National HIV Behavioral Surveillance (NHBS)

- 20 metropolitan statistical areas throughout the United States
- Funded by CDC, designed collaboratively
- Ongoing, cyclical study of three risk groups: men who have sex with men, IDU, and heterosexuals at increased risk of HIV infection
- Cross-sectional study design
- Fourth cycle of NHBS-IDU data collection in 2015



NHBS Objectives

- Determine frequency and correlates of HIV risk behaviors
- Assess HIV testing history and patterns
- Assess exposure to and use of HIV prevention services
- Estimate the prevalence of HIV infection
- Understand trends in risk and prevalence



NHBS-IDU4 Eligibility Criteria

- Injected drugs not prescribed for participant in past 12 months
 - Verified through visible signs of injection (e.g., track marks)
 and/or knowledge of injection practices
- At least 18 years old
- Resident of NYC metropolitan statistical area
- Speaks English or Spanish




Respondent-Driven Sampling (RDS)

- 1. Study team recruit initial participants ("seeds") through street and facility-based outreach
- 2. Seeds then recruit 3-5 other participants who meet the eligibility criteria
- 3. Each of those 3-5 participants then recruits 3-5 more, and so on until the target sample size is met
 - Study team continually monitors recruitment chains to ensure demographic representativeness
 - Study incentives provided for the survey, blood tests, and peer recruitment
 - See www.respondentdrivensampling.org for more information



NHBS-IDU4 Recruitment Network Diagram



NHBS-IDU4 Statistical Analysis

- Weighted analysis conducted with RDS Analysis Tool (RDSAT) 7.1 and SAS 9.3
- RDS weighting may reduce recruitment biases common in chain-referral methods (preferential ingroup recruitment [homophily] and large networks)
- If methodological assumptions are met, RDSAT may estimate generalizable population proportions (%'s) but not population sizes (n's)




NHBS-IDU4 Statistical Analysis

- Basic descriptive frequencies of demographics, risks, and use of HIV testing and prevention services
- Chi-square tests (categorical variables) and Wilcoxon tests (non-normal continuous variables) were used to compare differences in risk among IDUs who did not self-report as HIV-positive (n=468)
- Overall prevalence of HIV infection determined by confirmed Western Blot
- Seeds (n=23) excluded from all analyses



NHBS-IDU4 Sample





Sociodemographics

Demographics

Race/Ethnicity		Age	
Hispanic/Latino	45%	18-29	12%
Black	40%	30-39	24%
White	15%	40-49	31%
Other	1%	50+	33%
Gender		Birthplace	
Male	58%	United States	81%
Female	40%	Puerto Rico	17%
Transgender	2%	Foreign	2%



Demographics

Income		Education	
Less than \$10k/year	73%	<high school<="" td=""><td>34%</td></high>	34%
\$10k or more/year	27%	High School Grad+	66%
Marital Status		Sexual Identity	
		-	
Never Married	60%	Heterosexual	83%
Never Married Currently Married	60% 18%		83% 17%



Demographics

Homelessness		Borough of residence			
Past 12 months	61%	Bronx	40%		
Currently	48%	Brooklyn	40%		
		Manhattan	15%		
Jailed for more than	24 hours	Queens	5%		
Past 12 Months	32%	Staten Island	1%		



Injection Drug Use

Lifetime Injection History, by Race/Ethnicity

NYC NHBS-IDU4, 2015, n=506


	Overall	Black	Hispanic/ Latino	White
	M	edian (Interq	uartile Range)	
Current Age*	44 (21)	50 (12)	44 (13)	33.5 (14)
Age at First Injection	20 (10)	20 (11)	20 (10)	20 (9)
Years Since First Injection*	20 (20)	26 (22)	21 (19)	11 (14)

^{*}p<0.0001

Black and Hispanic/Latino IDUs were older and injected for a longer period of time, compared to white IDUs




Most Common Injection Location






Frequency of Drugs* Injected (Past 12 Months)





Syringe Sources (Past 12 Months)

NYC NHBS-IDU4, 2015, n=506






55% of IDUs obtained syringes *only* from sterile sources 16% obtained syringes *only* from potentially unsterile sources

Syringe Reuse and Sharing (Past 12 Months) among HIV-/Unk.

NYC NHBS-IDU4, 2015, n=468 (HIV-/Unk. IDU)





Syringe reuse: not using a new, sterile needle when injecting Receptive sharing: using a needle after someone else injected with it Distributive sharing: giving a needle to someone else after using it to inject with

Syringe Reuse and Sharing (Past 12 Months) among HIV-/Unk.


NYC NHBS-IDU4, 2015, n=468 (HIV-/Unk. IDU)

- IDUs who shared receptively had a mean 4.1 and a median
 1.5 partners who gave them used syringes
- IDUs who shared distributively had a mean 5.9 and a median
 2 partners to whom they gave their used syringes



Other Equipment Sharing in Past 12 Months among HIV-/Unk.


NYC NHBS-IDU4, 2015, n=468 (HIV-/Unk. IDU)





Syringe Reuse and Sharing in Past 12 Months among Self-Reported HIV+

NYC NHBS-IDU4, 2015, n=38 (self-reported HIV+)





Syringe reuse: not using a new, sterile needle when injecting Receptive sharing: using a needle after someone else injected with it Distributive sharing: giving a needle to someone else after using it to inject with

Syringe Reuse and Sharing in Past 12 Months among Self-Reported HIV+


NYC NHBS-IDU4, 2015, n=38 (self-reported HIV+)

- IDUs who shared receptively had a mean 1.8 and a median
 1.5 partners who gave them used syringes
- IDUs who shared distributively had a mean 1.3 and a median 1 partners to whom they gave their used syringes




Non-Injection Drug & Alcohol Use

Frequency of Non-Injection Drugs Used (Past 12 Months)





Alcohol Use (Past 30 Days)






Sexual Activity

Sexual Partnerships (Past 12 Months)

NYC NHBS-IDU4, 2015, n=460 (HIV-/Unk. IDU; transgender persons excluded)





^{*}For men, defined as giving money or drugs in exchange for sex with casual partners. For women, defined as receiving money or drugs in exchange for sex with casual partners.

Number of Heterosexual Partners by Participant Gender (Past 12 Months)

	To	Total		Men		Women	
	Mean	Median	Mean	Median	Mean	Median	
Main	0.93	1	0.94	1	0.90	1	
Casual	5.6	1	5.6	1	5.5	1	
All Types	6.5	2	6.6	2	6.4	2	



Number of Heterosexual Exchange Partners by Participant Gender (Past 12 Months)

	Total		Men		Women	
	Mean	Median	Mean	Median	Mean	Median
Exchange*	1.9	0	1.0	0	4.3	0
				<i>p</i> <.0	001	



^{*}For men, defined as giving money or drugs in exchange for sex with casual partners. For women, defined as receiving money or drugs in exchange for sex with casual partners.

Risk Behaviors with Heterosexual Partners by Participant Gender (Past 12 Months)

	Total	Men	Women	
	%	%	%	<i>p</i> *
Condomless Vaginal Sex (CVS)	74.5	73.7	76.9	0.57
Condomless Anal Sex (CAS)	22.4	22.5	22.3	0.96
CVS or CAS	76.6	76.0	78.2	0.68
CVS or CAS w/ Casual Partner	30.8	31.6	28.7	0.57
≥ 3 Total Sex Partners	24.3	25.0	22.3	0.54



^{*}p-value<0.05 indicates difference between men and women


Risk Behaviors with Heterosexual Partners by Participant Age (Past 12 Months)

	Total	18-29	30-39	40+	
	%	%	%	%	p*
Condomless Vaginal Sex (CVS)	74.6	78.8	73.8	73.8	0.75
Condomless Anal Sex (CAS)	22.5	36.3	27.5	16.9	0.001
CVS or CAS	76.6	83.0	75.1	75.5	0.51
CVS or CAS w/ Casual Partner	30.8	35.2	29.7	30.1	0.69
≥ 3 Total Sex Partners	24.3	36.0	22.3	22.2	0.05




^{*}p-value <0.05 indicates difference across age groups

Condomless Sex in Past 12 Months and Last Sex, by Participant Race*





Risk Characteristics of Last Heterosexual Partner, by Participant Gender






^{*}Participant reported having sex with other people during the past 12 months when they were having a sexual relationship with this partner

Risk Characteristics of Last Heterosexual Partner, by Participant Gender

NYC NHBS-IDU4, 2015, n=381 (HIV-/Unk. IDU with Heterosexual Partners)






^{*}Participant was asked whether last partner definitely did, probably did, probably did not, or definitely did not have the risk characteristic.

HIV Testing and Other Healthcare

Healthcare and Drug Treatment Encounters (Past 12 Months)


NYC NHBS-IDU4, 2015, n=506





HIV Testing History by Risk Group


NYC NHBS (HET, MSM, and IDU), 2013-15





Offered HIV Test by Medical Provider (Past 12 Months)

NYC NHBS-IDU4, 2015, n=422 (HIV-/Unk. IDU Who Visited a Medical Provider)






HIV Prevention Activities

HIV Prevention Activities (Past 12 Months)


NYC NHBS-IDU4, 2015, n=506





Pre-exposure Prophylaxis Awareness and Use

NYC NHBS-IDU4, 2015, n=468 (HIV-/Unk. IDU)





HIV & HCV Prevalence

HIV Prevalence

Health

NYC NHBS-IDU4, 2015, n=506 (Tested in Study)


	HIV-Positive	95% CI
Overall	8.2%	5.9% – 10.5%
By Race*		
Black	11.7%	6.7% – 16.6%
Hispanic/Latino	8.4%	5.1% - 11.7%
White	2.9%	0.35% - 6.1%
By Gender*		
Male	5.8%	3.4% - 8.1%
Female	13.0%	7.6% – 18.3%
By Age		
18-29	0	0
30-39	4.7%	1.0% - 8.4%
40+	11.3%	8.0% - 14.7%

^{*}Other race (including Asian, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander) and transgender persons excluded due to small sample sizes.

Hepatitis C Virus Prevalence

NYC NHBS-IDU4, 2015

Of the 506 participants, 499 (99%) underwent rapid HCV testing for lifetime infection with HCV.





*Among those with a positive rapid test and who underwent confirmatory testing. Of the participants with a positive rapid test, 34% (n=86) were not able to provide a blood sample for confirmatory testing because phlebotomy was unavailable.

Lifetime Hepatitis C Virus Prevalence

NYC NHBS-IDU4, 2015, n=499 (Tested in Study)

	Lifetime HCV infection	95% CI
Overall	51.0%	46.6% – 55.4%
By Race*		
Black	24.9%	18.0% - 31.9%
Hispanic/Latino	63.6%	57.6% – 69.6%
White	61.2%	51.4% - 71.0%
By Gender*		
Male	56.3%	51.1% - 61.6%
Female	39.1%	31.1% – 47.2%
By Age		
18-29	31.5%	20.3% – 42.6%
30-39	60.8%	52.0% - 69.7%
40+	51.6%	46.0% - 57.1%



^{*}Other race (including Asian, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander) and transgender persons excluded due to small sample sizes.

Conclusions

Summary

- Participants reported frequent encounters with exchange programs, pharmacies, medical providers, and other prevention outlets
- However, there were continuing injection-related and sexual risk behaviors
- High levels of HIV infection were found, with notable disparities by race/ethnicity
- Many IDU face structural risk factors that may increase HIV infection risk: poverty, homelessness, and arrest/incarceration



Strengths

- Large dataset with data on multiple HIV risk factors
- National, standardized survey and protocol
- Extensive formative research supporting data collection
- RDS can reach "hidden" populations of IDUs who may not access treatment programs and other institutionalized settings
- Local questions developed to explore issues relevant specifically to NYC IDUs



Limitations

- RDS-based estimates may not be generalizable to population of New York City IDUs if methodological assumptions are not met
- RDS can only recruit those who are socially networked to other IDUs
- All data except HIV and HCV serostatus were collected by self-report, and may be biased by recall error or social desirability and self-selection



NYC National HIV Behavioral Surveillance Team - IDU4

NYC Department of Health

Principal Investigators
Alan Neaigus
Project Director
Katie Reilly
Project Coordinator/Field Supervisor
Valentina Ramirez
Olga Gromadzka

Data Collection Team
Anna Andel
Joshua Hinkson
Nicole Holder
Emma Molina
Nevin Rao

CDC
Gabriela Paz-Bailey
Dita Broz

CDC Grant#: 5U1BPS003262-05



Contact

Alexis Rivera, MPH

NHBS Project Director

HIV Epidemiology and Field Services Program

NYC Department of Health

Phone: 347-396-7750

Email: arivera6@health.nyc.gov

